

# MARKET REPORT



## PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

## Summary

GlobalData estimates sales of HF therapeutics to be approximately \$3.7B across the 7MM in 2016, encompassing the US, the five major European markets (5EU: France, Germany, Italy, Spain and UK), and Japan. By 2026, GlobalData expects the HF market to grow at a strong Compound Annual Growth Rate (CAGR) of 15.7%, reaching sales of \$16.1B by the end of the forecast period. Chronic HF therapeutics accounted for 95.9% of the total HF market in 2015, and despite the launch of a new acute HF therapy, this figure is expected to increase slightly to 98.7% by 2026. GlobalData expects uptake of Novartis' Entresto will be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of \$8.6B in 2022.

## Key Questions Answered

- The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfil these unmet needs of the market? Key Opinion Leaders (KOLs) interviewed by GlobalData provide insights and highlight opportunities for drug developers.
- The HF market is crowded with cheap, generic, "me-too" drugs, making it a particularly difficult market to penetrate. The current late-stage pipeline consists of several chronic HF therapies, and three novel acute HF therapies. How will the market be impacted by the launch of these drugs? Which of the marketed and pipeline drugs will have the highest peak sales at the highest CAGR, and why?
- Will Entresto become the new standard-of-care in the chronic HF market? What are the main barriers a new therapy faces when entering the HF market?

## Scope

- Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

## Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the HF therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HF therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM HF therapeutics market from 2016-2026.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

## Additional Details

**Publisher :** Global Data

**Reference :** GDHC146PIDR

**Number of Pages :** 241

**Report Format :** PDF

**Publisher Information :**



**GlobalData** »

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026 [Report Updated: 01-07-2017]

- 1 Table of Contents1 Table of Contents 21.1 List of Tables 91.2 List of Figures 102 Heart Failure: Executive Summary 122.1 The HF Market Will Exhibit Strong Growth Between 2016 and 2026 122.2 Label Expansion to HF with Preserved Ejection Fraction Will Fuel Market Growth 142.3 The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline 152.4 Opportunities Remain for All Aspects of HF, But What the Market Really Needs Is a Transformational Therapy 162.5 Entresto Will Dominate the HF Market 162.6 What Do Physicians Think? 173 Introduction 203.1 Catalyst 203.2 Related Reports 204 Disease Overview 214.1 Etiology and Pathophysiology 214.1.1 Etiology 214.1.2 Pathophysiology 234.1.3 Biomarkers/Targets of Interest 254.2 Classification or Staging Systems 264.3 Symptoms 274.4 Prognosis 284.5 Quality of Life 295 Epidemiology 305.1 Disease Background 305.2 Risk Factors and Comorbidities 315.3 Global and Historical Trends 325.4 Forecast Methodology 345.4.1 Sources 355.4.2 Forecast assumptions and methods 405.4.3 Diagnosed Incident Cases of HF by EF 435.4.4 Diagnosed Incident Cases of HF by Ventricular Dysfunction 455.4.5 Acute HF Hospitalizations 455.4.6 Hospital Length of Stay for Acute HF Hospitalization 475.4.7 Diagnosed Prevalent Cases of CHF 485.4.8 Diagnosed Prevalent Cases of CHF by EF 515.4.9 Diagnosed Prevalent Cases of CHF by NYHA Classes 525.5 Epidemiological Forecast for Heart Failure (2016-2026) 545.5.1 Diagnosed Incident Cases of HF 545.5.2 Age-Specific Diagnosed Incident Cases of HF 555.5.3 Sex-Specific Diagnosed Incident Cases of HF 555.5.4 Diagnosed Incident Cases of HF by EF 565.5.5 Diagnosed Incident Cases of HF by VD 575.5.6 Acute HF Hospitalizations 585.5.7 Hospital Length of Stay for Acute HF Hospitalization 615.5.8 Diagnosed Prevalent Cases of CHF 615.5.9 Age-Specific Diagnosed Prevalent Cases of CHF 625.5.10 Sex-Specific Diagnosed Prevalent Cases of CHF 635.5.11 Diagnosed Prevalent Cases of CHF by EF 645.5.12 Diagnosed Prevalent Cases of CHF by NYHA Class 655.6 Discussion 685.6.1 Epidemiological Forecast Insight 685.6.2 Limitations of Analysis 695.6.3 Strengths of Analysis 696 Disease Management 706.1 Diagnosis Overview 706.2 Treatment Overview 736.2.1 Treatment Guidelines and Leading Prescribed Drugs 736.2.2 Clinical Practice 756.3 US 796.4 5EU 816.5 Japan 847 Competitive Assessment 877.1 Overview 877.2 Angiotensin-Converting Enzyme Inhibitors 887.2.1 Overview 887.2.2 Efficacy 897.2.3 Safety 897.2.4 Forecast 907.3 Angiotensin Receptor Blockers 907.3.1 Overview 907.3.2 Efficacy 917.3.3 Safety 917.3.4 Forecast 927.4 Entresto (Sacubitril + Valsartan) 927.4.1 Overview 927.4.2 Efficacy 997.4.3 Safety 1017.4.4 SWOT Analysis 1037.4.5 Forecast 1047.5 Diuretics 1057.5.1 Overview 1057.5.2 Efficacy 1067.5.3 Safety 1077.5.4 Forecast 1077.6 Beta Blockers 1087.6.1 Overview 1087.6.2 Efficacy 1097.6.3 Safety 1097.6.4 Forecast 1107.7 Procoralan (Ivabradine) 1107.7.1 Overview 1107.7.2 Efficacy 1137.7.3 Safety 1157.7.4 SWOT Analysis 1167.7.5 Forecast 1167.8 Mineralocorticoid Receptor Antagonists 1177.8.1 Overview 1177.8.2 Efficacy 1197.8.3 Safety 1197.8.4 Forecast 1207.9 Digoxin 1207.9.1 Overview 1207.9.2 Efficacy 1217.9.3 Safety 1227.9.4 Forecast 1227.10 Pharmacological Therapies for Acute HF 1228 Unmet Needs and Opportunity Assessment 1248.1 Overview 1248.2 Lack of Therapies for HF-PEF Patients 1258.2.1 Unmet Need 1258.2.2 Gap Analysis 1268.2.3 Opportunity 1278.3 Lack of Therapies for Acute HF 1288.3.1 Unmet Need 1288.3.2 Gap Analysis 1298.3.3 Opportunity 1298.4 Lack of Therapies for Patients with Renal Impairment 1308.4.1 Unmet Need 1308.4.2 Gap Analysis 1308.4.3 Opportunity 1318.5 Preventative Therapies for Patients at Risk of Developing HF 1318.5.1 Unmet Need 1318.5.2 Gap Analysis 1328.5.3 Opportunity 1338.6 Use of Optimal Doses of HF Therapies 1338.6.1 Unmet Need 1338.6.2 Gap Analysis 1358.6.3 Opportunity 1358.7 Patient Compliance 1368.7.1 Unmet Need 1368.7.2 Gap Analysis 1368.7.3 Opportunity 1378.8 Early Detection and Treatment of Patients with Worsening Chronic HF 1388.8.1 Unmet Need 1388.8.2 Gap Analysis 1388.8.3 Opportunity 1398.9 Dynamic Management of Patients with HF 1398.9.1 Unmet Need 1398.9.2 Gap Analysis 1408.9.3 Opportunity 1418.10 Options for Advanced HF Patients Who Are Unable to Receive a Heart Transplant 1428.10.1 Unmet Need 1428.10.2 Gap Analysis 1428.10.3 Opportunity 1438.11 Better Risk Stratification of Patients Admitted to the ED with Acute HF and Enhanced Outpatient Care 1438.11.1 Unmet Need 1438.11.2 Gap Analysis 1438.11.3 Opportunity 1449 Pipeline Assessment 1459.1 Overview 1459.2 Drugs in Clinical Development 1479.2.1 Pipeline Drugs by Patient Population 1479.3 Promising Drugs in Clinical Development 1489.4 Omecamtiv Mecarbil 1489.4.1 Overview 1489.4.2 Efficacy 1519.4.3 Safety 1529.4.4 Dosing and Formulation 1529.4.5 Potential Clinical and Commercial Positioning 1529.4.6 SWOT Analysis 1549.4.7 Forecast 1549.5 Vericiguat 1559.5.1 Overview 1559.5.2 Efficacy 1569.5.3 Safety 1579.5.4

Dosing and Formulation 1589.5.5 Potential Clinical and Commercial Positioning 1589.5.6 SWOT Analysis 1599.5.7 Forecast 1599.6 RT-100 1609.6.1 Overview 1609.6.2 Efficacy 1619.6.3 Safety 1619.6.4 Dosing and Formulation 1629.6.5 Potential Clinical and Commercial Positioning 1629.6.6 SWOT Analysis 1639.6.7 Forecast 1639.7 CXL-1427 1639.7.1 Overview 1639.7.2 Efficacy 1659.7.3 Safety 1659.7.4 Dosing and Formulation 1659.7.5 Potential Clinical and Commercial Positioning 1659.7.6 SWOT Analysis 1669.7.7 Forecast 1669.8 Other Drugs in Development 16710 Current and Future Players 16910.1 Overview 16910.2 Trends in Corporate Strategy 17110.3 Amgen and Cytokinetics 17310.3.1 Overview 17310.3.2 Portfolio Assessment 17410.4 Bayer (and Merck & Co.) 17410.4.1 Overview 17410.4.2 Portfolio Assessment 17510.5 Bristol-Myers Squibb 17610.5.1 Overview 17610.5.2 Portfolio Assessment 17610.6 Les Laboratoires Servier 17710.6.1 Overview 17710.6.2 Portfolio Assessment 17810.7 Novartis 17910.7.1 Overview 17910.7.2 Portfolio Assessment 18010.8 Renova Therapeutics 18110.8.1 Overview 18110.8.2 Portfolio Assessment 18111 Market Outlook 18311.1 Global Markets 18311.1.1 Forecast 18311.1.2 Drivers and Barriers - Global Issues 18611.2 US 18811.2.1 Forecast 18811.2.2 Key Events 19011.2.3 Drivers and Barriers 19011.3 5EU 19111.3.1 Forecast 19111.3.2 Key Events 19311.3.3 Drivers and Barriers 19411.4 Japan 19511.4.1 Forecast 19511.4.2 Key Events 19711.4.3 Drivers and Barriers 19712 Appendix 19912.1 Bibliography 19912.2 Abbreviations 21612.3 Methodology 22212.3.1 Forecasting Methodology 22212.3.2 Diagnosed Prevalent Chronic HF 22212.3.3 Diagnosed Incidence of Acute HF 22212.3.4 Percent Drug-Treated Patients 22312.3.5 Treatment of HF with Reduced Ejection Fraction Versus HF with Preserved Ejection Fraction 22312.3.6 Drugs Included in Each Therapeutic Class 22312.3.7 Launch and Patent Expiry Dates 22412.3.8 General Pricing Assumptions 22412.3.9 Individual Drug Assumptions 22512.3.10 Generic Erosion 23012.3.11 Pricing of Pipeline Agents 23012.4 Primary Research - KOLs Interviewed for this Report 23212.5 Primary Research - Payers Included in this Study 23412.6 Primary Research - Prescriber Survey 23612.7 About the Authors 23712.7.1 Analyst 23712.7.2 Therapy Area Director 23712.7.3 Epidemiologist 23712.7.4 Managing Epidemiologists 23812.7.5 Global Director of Therapy Analysis and Epidemiology 23912.7.6 Global Head and EVP of Healthcare Operations and Strategy 24012.8 About GlobalData 24112.9 Contact Us 24112.10 Disclaimer 241

# List Of Tables in PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026 [Report Updated: 01-07-2017]

## 1.1 List of Tables

Table 1: Heart Failure: Key Metrics in the 7MM 12

Table 2: Types of Chronic HF 22

Table 3: The leading causes, as well as other less common causes, of HF. 23

Table 4: The compensatory mechanisms that are activated in a patient with HF. 24

Table 5: Key Diagnostic and prognostic biomarkers in HF. 25

Table 6: Overview of Clinically Relevant Biomarkers in HF 26

Table 7: shows a comparison of these two HF classification systems. 27

Table 8: Symptoms of Heart Failure 28

Table 9: Risk Factors and Comorbidities for HF 32

Table 10: NYHA Functional Classification for CHF (Classes I-IV). 35

Table 11: 7MM, Diagnosed Incident Cases of HF, Both Sexes, Ages  $\geq 45$  Years, N, Selected Years 2016-2026 54

Table 12: 7MM, Diagnosed Prevalent Cases of CHF, Both Sexes, Ages  $\geq 45$  Years, N, Selected Years 2016-2026 62

Table 13: lists the common factors that precipitate acute HF. 73

Table 14: HF Treatment guidelines most commonly adhered to by physicians in the 7MM. 73

Table 15: summarizes the chronic HF-REF medications and drug classes most commonly used in the US, 5EU, and Japan, based on GlobalData's primary and secondary research. 74

Table 16: Country Profile - US 80

Table 17: Country Profile - 5EU 82

Table 18: Country Profile - Japan 85

Table 19: Summary of major clinical trials assessing the efficacy of ACE inhibitors in HF-REF patients. 89

Table 20: Summary of major clinical trials assessing the efficacy of ARBs in HF-REF patients. 91

Table 21: Product Profile - Entresto 99

Table 22: Efficacy of Entresto, PARADIGM-HF 100

Table 23: Safety of Entresto, PARADIGM-HF 102

Table 24: Entresto SWOT Analysis, 2016 103

Table 25: Summary of major clinical trials assessing the efficacy of beta blockers in HF-REF patients. 109

Table 26: Product Profile - Procoralan	113
Table 27: Efficacy of Procoralan, SHIFT study	114
Table 28: Procoralan SWOT Analysis, 2016	116
Table 29: Unmet Need and Opportunity in HF, 2016	125
Table 30: Product Profile - Omecamtiv Mecarbil	151
Table 31: Efficacy of Omecamtiv Mecarbil, COSMIC-HF	151
Table 32: Omecamtiv Mecarbil SWOT Analysis, 2016	154
Table 33: Product Profile - Vericiguat	156
Table 34: Efficacy of Vericiguat, SOCRATES-Reduced	157
Table 35: Safety of Vericiguat, SOCRATES-Reduced	157
Table 36: Vericiguat SWOT Analysis, 2016	159
Table 37: Product Profile - RT-100	161
Table 38: RT-100 SWOT Analysis, 2016	163
Table 39: Product Profile - CXL-1427	165
Table 40: CXL-1427 SWOT Analysis, 2016	166
Table 41: Drugs in Development for Heart Failure, 2016	167
Table 42: Key Companies in the Heart Failure Market in the 7MM, 2016	170
Table 43: Amgen's HF Portfolio Assessment, 2016	174
Table 44: Bayer's HF Portfolio Assessment, 2016	176
Table 45: Bristol-Myers Squibb HF Portfolio Assessment, 2016	177
Table 46: Servier's HF Portfolio Assessment, 2016	179
Table 47: Novartis' Disease Portfolio Assessment, 2016	181
Table 48: Renova Therapeutics' Disease Portfolio Assessment, 2016	182
Table 49: Heart Failure Market - Global Drivers and Barriers, 2016-2026	186
Table 50: Key Events Impacting Sales for HF in the US, 2016-2026	190
Table 51: HF Market - Global Drivers and Barriers in the US, 2016-2026	190
Table 52: Key Events Impacting Sales for Heart Failure in the 5EU, 2016-2026	193
Table 53: Heart Failure Market - Global Drivers and Barriers in the 5EU, 2016-2026	194
Table 54: Key Events Impacting Sales for Heart Failure in Japan, 2016-2026	197
Table 55: Heart Failure Market - Global Drivers and Barriers in Japan, 2016-2026	197
Table 56: Key Historical and Projected Launch Dates for HF	224



Table 57: Key Historical and Projected Patent Expiry Dates for Heart Failure 224

Table 58: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 236

# List Of Figures, Charts and Diagrams in PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026 [Report Updated: 01-07-2017]

## 1.2 List of Figures

Figure 1: Global Sales for Heart Failure by Country, 2016 and 2026 14

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2016-2026 17

Figure 3: Changes in Cardiac Structure in HF 22

Figure 4: RAAS Mechanism of Action 24

Figure 5: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Men and Women, Ages  $\geq 45$  Years, 2016 33

Figure 6: 7MM, Age-Standardized Diagnosed Prevalence of CHF (%), Men and Women, Ages  $\geq 45$  Years, 2016 34

Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF 35

Figure 8: 7MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF 36

Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by EF 37

Figure 10: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by EF 37

Figure 11: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by Ventricular Dysfunction 38

Figure 12: 7MM, Sources Used to Forecast Hospitalizations for Acute HF 38

Figure 13: 7MM, Sources Used to Forecast Hospitalizations for Acute HF by Worsening CHF, Advanced HF, and de novo HF 39

Figure 14: 7MM, Sources Used to Forecast Hospital Length of Stay for Acute HF Hospitalization 39

Figure 15: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class 40

Figure 16: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, Ages  $\geq 45$  Years, N, 2016 55

Figure 17: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages  $\geq 45$  Years, N, 2016 56

Figure 18: 7MM, Diagnosed Incident Cases of HF by EF, Both Sexes, Ages  $\geq 45$  Years, N, 2016 57

Figure 19: 7MM, Diagnosed Incident Cases of HF by VD, Both Sexes, Ages  $\geq 45$  Years, N, 2016 58

Figure 20: 7MM, Acute HF Hospitalizations, Both Sexes, Ages  $\geq 45$  Years, N, 2016 to 2026 59

Figure 21: 7MM, Acute HF Hospitalizations by Patients Admitted and Discharged, Both Sexes, Ages  $\geq 45$  Years, 2016 59

Figure 22: 7MM, Acute HF Hospitalizations by Worsening Chronic HF, Advanced HF, and De Novo HF, Both Sexes, Ages  $\geq 45$  Years, 2016 60

Figure 23: 7MM, Hospital Length of Stay for Acute HF Hospitalization, Both Sexes, Ages  $\geq 45$  Years, N, 2016 61

Figure 24: 7MM, Age-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages  $\geq 45$  Years, N, 2016 63

Figure 25: 7MM, Sex-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages  $\geq$ 45 Years, N, 2016 64

Figure 26: 7MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, Ages  $\geq$ 45 Years, N, 2016 65

Figure 27: 7MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, Ages  $\geq$ 45 Years, N, 2016 66

Figure 28: 7MM, Diagnosed Prevalent Cases of CHF with REF by NYHA Class, Both Sexes, Ages  $\geq$ 45 Years, N, 2016 67

Figure 29: 7MM, Diagnosed Prevalent Cases of CHF with PEF by NYHA Class, Both Sexes, Ages  $\geq$ 45 Years, N, 2016 68

Figure 30: Diagnostic Algorithm for Chronic HF 71

Figure 31: Diagnostic Algorithm for Acute HF 72

Figure 32: HF based on the ACCF/AHA staging system 75

Figure 33: Classification of acute HF patients 77

Figure 34: Management of acute HF patients 78

Figure 35: Heart Failure - Drugs in Development, 2016 147

Figure 36: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2016-2026 148

Figure 37: Company Portfolio Gap Analysis in Heart Failure, 2016-2026 171

Figure 38: Global Sales for Chronic HF by Country, 2016 and 2026 184

Figure 39: Global Sales for acute HF by Country, 2016 and 2026 185

Figure 40: Sales for Chronic HF by Drug Class in the US, 2016 and 2026 189

Figure 41: Sales for Chronic HF by Drug Class in the 5EU, 2016 and 2026 192

Figure 42: Sales for HF by Drug Class in Japan, 2016 and 2026 196

# How to Buy...

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026 [Report Updated: 01-07-2017]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/119062>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$10995** | Single User Price
- \$21990** | Site License Price
- \$32985** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.